Comparing the Outcomes of Anti-VEGF Treatment for Choroidal Neovascular Membrane

Authors

  • Md Mahboobur Rahman Bhuyan Junior Consultant (Ophthalmology), Sheikh Fazilatunnesa Mujib Eye Hospital & Training Institute, Gopalganj, Bangladesh
  • Syeed Mehbub Ul Kadir Assistant Professor (Ophthalmology), Sheikh Fazilatunnesa Mujib Eye Hospital & Training Institute, Gopalganj, Bangladesh
  • Jamsed Faridi Resident Surgeon, Sheikh Fazilatunnesa Mujib Eye Hospital & Training Institute, Gopalganj, Bangladesh
  • Naznin Sultana Junior Consultant (Ophthalmology), Sheikh Fazilatunnesa Mujib Eye Hospital & Training Institute, Gopalganj, Bangladesh
  • Mohammad Afzal Mahfuz Ullah Associate Professor (Ophthalmology), Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Shah Noor Hasan Associate Professor (Ophthalmology), Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/cbmj.v13i2.75318

Keywords:

Choroidal neovascular membrane, bevacizumab, ranibizumab, anti-vascular endothelial growth factor

Abstract

This quasi-experimental study was conducted in the Department of Ophthalmology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, and Bangladesh Eye Hospital, Dhaka, Bangladesh, from March 2020 to August 2021, to compare the efficacy of Bevacizumab and Ranibizumab on patients with choroidal neovascular membrane (CNVM) due to age-related macular degeneration (AMD). A total of 34 eyes of 34 participants with CNVM in AMD divided into Group A, received monthly intravitreal ranibizumab (0.5 mg in 0.05 ml) and Group B, bevacizumab (1.25 mg in 0.05 ml) for 3 consecutive months. Before treatment, mean BCVA was found 37.9412±16.68259 in group A and 35.2941±12.68249 in group B. After treatment, the mean best-corrected visual acuity (BCVA) was found 53.5294±14.97547 in group A and 48.8235±13.75334 in group B. The differences were not statistically significant (p>0.05) between two groups. The improvement in BCVA was highly significant (p<0.0001) in both groups before and after giving intravitreal bevacizumab and ranibizumab. Before treatment, mean central macular thickness (OCT) was found in 344.8824±82.51582 μm in group A and 360.1765±82.22016 μm in group B. After treatment, OCT was found 255.18±71.852 μm in group A and 241.76±42.405 μm in group B. The differences were not statistically significant (p>0.05) between two groups. However, the improvement by decreasing macular thickness was highly significant (p<0.0001) in both groups before and after giving intravitreal bevacizumab and ranibizumab. Treatment with intravitreal bevacizumab or ranibizumab was associated with a similar improvement in mean visual acuity and decreasing central macular thickness by 4 months.

CBMJ 2024 July: vol. 13 no. 02 P: 265-273

Downloads

Download data is not yet available.
Abstract
64
PDF
62

Downloads

Published

2024-08-07

How to Cite

Bhuyan, M. M. R., Kadir, S. M. U., Faridi, J., Sultana, N., Ullah, M. A. M., & Hasan, S. N. (2024). Comparing the Outcomes of Anti-VEGF Treatment for Choroidal Neovascular Membrane. Community Based Medical Journal, 13(2), 265–273. https://doi.org/10.3329/cbmj.v13i2.75318

Issue

Vol. 13 No. 2 (2024)

Section

Original Articles

License

Copyright (c) 2024 Md Mahboobur Rahman Bhuyan, Syeed Mehbub Ul Kadir, Jamsed Faridi, Naznin Sultana, Mohammad Afzal Mahfuz Ullah, Shah Noor Hasan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

No part of the materials published in this journal may be reproduced, stored or transmitted without prior written permission of the editorial board.